The addition of nanoparticles of low molecular weight PLGA to those of high molecular weight reduced the release rate at the initial release phase, but that at the second release phase was almost entirely unaffected by mixing ratio.
According to Fig. 5 to Fig. 7, compared with hydrophobic small molecular drug, hydrophilic small molecular drug reached a higher cumulative release rate in a shorter period.
Protein molecular weight inversely affected the release rate, and loading with a higher protein concentration increased the mass but not the percent of initially loaded protein released daily.
In addition, cumulative release rate of hydrophilic small molecular drug was much higher than that of hydrophilic large molecular drugs.
The morphology of the composite particles was affected by release rate of toluene, the molecular weight of PS-b-PMMA, droplet size, and polymer composition.
Thus, our building blocks comprise populations that differ by microsphere mean diameter, polydispersity, and polymer molecular weight, giving three separate parameters that effect drug release rate, and from which we build a foundation for our tailored release.
Finally, the release rate could be controlled using different PEG molecular weights and concentrations.
A sustained release was observed for at least 42 days, with the release rate controlled by method of incorporation and polymer molecular weight.
The release rate of 6FAM exhibited a dependence on the molecular weight of PEG used in matrix formation.
The plasticizer amount and molecular weight (MW) together with the osmotic agent amount directly affect the release rate whereas the swellable polymer amount and viscosity together with the semi-permeable membrane (SPM) thickness inversely influence the release rate.
